Phylogica announced that there has been a change to its Board of Directors with the appointment of CEO Dr. Rohan Hockings to the Board; and the resignation of CSO Dr. Robert Hayes from the Board with effect from December 24, 2018. The changes have been made as part of the company's preparation for commercialisation of its Cell Penetrating Peptide platform on the back of a series of major technical milestones scheduled for delivery between now and mid-2019.